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Durability and tolerability of first-line regimens including two nucleoside 1 
reverse transcriptase inhibitors and raltegravir or ritonavir boosted-2 
atazanavir or -darunavir: data from the ICONA Cohort 3 
Abstract 4 
Background: We aimed to mimic the ACTG 5257 trial, comparing raltegravir (RAL), 5 
ritonavir-boosted atazavavir (ATV/r) and ritonavir-boosted darunavir (DRV/r) in the 6 
observational setting. 7 
Methods: All the ICONA patients starting a first cART with 2NRTI +ATV/r, DRV/r or 8 
RAL were included.  Primary end-point was treatment failure, ie virological failure 9 
(confirmed HIV-RNA>200copies/ml >6 months therapy) or discontinuation for any 10 
reason of the third drug. Secondary end-points: virological failure50 (50 copies/mL 11 
threshold), and discontinuation of the third drug due to intolerance/toxicity. Cox 12 
regression analyses were run to compare the risk of outcomes between the three 13 
regimens.  14 
Results: 2,249 patients were included, 985 (44%) initiated ATV/r, 1,023 (45%) DRV/r 15 
and 241 (11%) RAL; median follow-up of 3.6 years (IQR: 2.3-5.2). After controlling for 16 
baseline confounding factors, patients given ATV/r showed a 26% higher risk of 17 
treatment failure (TF) vs DRV/r (AHR 1.26, 95%CI 1.11-1.43); patients on RAL had a 18 
lower risk of TF vs ATV/r (AHR 0.81, 95%CI 0.66-0.99).  The probability of virological 19 
failure50 was significantly lower for people initiating RAL vs DRV/r (AHR 0.46, 95%CI 20 
0.24-0.87) or ATV/r (AHR 0.52, 95%CI 0.27-0.99). In addition, RAL was associated to a 21 
lower risk of discontinuation for toxicity vs both DRV/r (AHR: 0.37, 95%CI: 0.19-0.72) 22 
and ATV/r (AHR: 0.18, 95%CI: 0.09-0.34). ATV/r was associated with a higher risk of 23 
discontinuing due to toxicity (AHR 2.09, 95%CI 1.63-2.67) vs DRV/r. 24 
Conclusions: In our observational study, we confirmed higher risk of treatment failure 25 
and lower tolerability of ATV/r-based regimens as compared to those including DRV/r or 26 
RAL. 27 
Keywords: cohort study; antiretroviral regimens; therapy discontinuation; raltegravir;  28 
Boosted-atazanavir; boosted-darunavir. 29 
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Introduction 32 
Although newer drugs belonging to the integrase inhibitors class (raltegravir, dolutegravir 33 
and elvitegravir) as well as newer generation non-nucleoside reverse transcriptase inhibitors 34 
(NNRTI) (such as rilpivirine) are now the most commonly prescribed third agents in first-line 35 
combination antiretroviral therapy (cART), darunavir/r (DRV/r) and atazanavir/r (ATV/r) are 36 
still among the indicated alternative options in several treatment guidelines [1-3]. Indeed, 37 
ritonavir-boosted protease inhibitors (PI/r)-containing regimens retain strong supporting 38 
evidence of long-term clinical efficacy, and are still considered as first-line options in persons 39 
with low adherence or in cases with missing drug resistance tests before starting cART, due to 40 
their high genetic barrier [1-3].  41 
The ACTG 5257 trial has compared the efficacy and tolerability of three first-line regimens 42 
including ATV/r, DRV/r or raltegravir (RAL), in combination with tenofovir/emtricitabine 43 
(TDF/FTC) in 1,809 naïve subjects enrolled in clinical sites in the United States [4].  The trial 44 
demonstrated similar virological potency of the three regimens, even in patients starting cART 45 
at high viral load, and lower tolerability for ATV/r including regimens as compared to the other 46 
two drugs and also lower tolerability for DRV/r as compared to RAL.  47 
One limitation of the ACTG study is its open-label design, and people on ATV/r may have 48 
been more prone to switch their regimen for elevate bilirubin levels or the fear of a sustained 49 
elevation.    Moreover, ACTG 5257 showed results up to 3 years from the date of regimens 50 
initiation and longer terms estimates are currently lacking.   51 
We therefore aimed to conduct an analysis similar to that of the ACTG 5257 trial, by 52 
comparing the long-term durability and safety of first-line RAL-including regimens to therapies 53 
including either DRV/r or ATV/r but using observational data.  Our analysis also provides a 54 
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comparison of the effectiveness of the regimens when used in HIV-infected persons seen in 55 
routine clinical practice in Italy where, unlike the USA, there is no barrier to access to 56 
treatment and care. 57 
Methods 58 
The ICONA Foundation Study   59 
The Italian Cohort Naives Antinetrovirals (ICONA) Foundation Study is a multi-centre 60 
observational study of HIV-1-infected patients set up in 1997, including 51 centres of 61 
Infectious Diseases across Italy. Patients eligible to be included in the cohort are those starting 62 
cART when they are naive to antiretrovirals, regardless of the reason for which they had never 63 
been previously treated. Demographic (age, sex, risk factors for HIV, education, job, marital 64 
status), clinical (all clinical events, both HIV and non HIV related) and laboratory data and 65 
information on therapy (both HIV and non HIV) are collected and recorded using electronic 66 
data collection and updated at any new event or at least twice a year [www.icona.org]. Details 67 
of the study are described elsewhere [5].  68 
The ICONA Foundation study has been approved by IRB of all the participating centres. All 69 
patients sign a consent form to participate in ICONA, in accordance with the ethical standards 70 
of the committee on human experimentation and the Helsinki Declaration (1983 revision). The 71 
estimated percentage of refusal to participate the study is 5-10%. 72 
Patient population  73 
All the patients from the ICONA Foundation cohort who started their first cART regimen after 74 
January 1, 2008 (year in which RAL was licenced for use in Italy) with 2NRTI (either 75 
TDF+FTC or abacavir+lamivudine -ABC+3TC) + ATV/r or DRV/r or RAL were included in 76 
this analysis. We recorded the presence of comorbidities at ART initiation (baseline), defined 77 
as: any non AIDS-defining malignancy; cardiovascular events (acute myocardial infarction, 78 
coronary disease requiring invasive procedures, stroke); hepatic events (decompensated 79 
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cirrhosis, i.e. variceal bleeding, porto-systemic encephalopathy, refractory ascites); kidney 80 
injury (onset of a confirmed estimated glomerular filtrate rate [eGFR] <60 ml/min using 81 
Modification of Diet in Renal Disease -MDRD- formula or kidney failure requiring dialysis or 82 
transplantation). All causes of discontinuation are collected in the ICONA database as reported 83 
by the treating physicians who are asked to indicate which the main reason for stopping was. 84 
Reasons include simplification (defined either as the reduction of number of drugs or the 85 
decrease in daily doses or pills), intolerance, toxicity, failure (virological, immunological or 86 
clinical), non-adherence, planned interruption (including end of pregnancy and medical 87 
decision) and other causes (patients decision, pregnancy, enrolment or ending of a clinical trial 88 
and drug-drug interaction). 89 
Study outcomes 90 
The response to the initial regimens was compared according to the specific third drug started 91 
with respect of a number of end-points. Our primary objective was to compare treatment failure 92 
between the three regimens (RAL, DRV/r, ATV/r). The composite end-point of treatment 93 
failure  was defined as virological failure (confirmed HIV-RNA>200 copies/ml after 6 months 94 
of therapy) or discontinuation of the third drug of the regimen for any reasons. Secondary end-95 
pointes included: 96 
 virological failure 50: confirmed HIV-RNA >50 copies/mL after 6 months of therapy  97 
 discontinuation of DRV/r or ATV/r or RAL because of intolerance/toxicity. 98 
Discontinuations of the NRTI backbones have been ignored in this analysis.  99 
Mean CD4 change from baseline to 2nd years of follow-up according to the third drug were also 100 
analysed in a subset of the study population with complete CD4 count data.   101 
Patients were followed up from date of starting one of the studied regimens (i.e. baseline) to the 102 
first end-point event, November 15th, 2017, death or loss to follow-up. 103 
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Statistical analyses   104 
For the comparison of characteristics at time of treatment initiation among the three groups, 105 
Chi-square or Kruskal-Wallis test were used as appropriate. Survival analysis with Kaplan-106 
Meier curves were used and the probability of the outcome was estimated together with 95% 107 
confidence interval for each time point. Log-rank test was used to test the equality of survival 108 
curves. 109 
Cox regression analysis stratified by clinical site was employed to compare the risk of primary 110 
and secondary outcomes by means of computing unadjusted and adjusted (after controlling for 111 
potential measured confounding factors) hazard ratios. The proportional-hazards assumption 112 
was verified testing the interaction between the predictors and natural logarithm of survival 113 
time. All variables considered in the univariable model have been also included in the 114 
multivariable model. The adjusted analysis included the following a priori chosen, time-fixed 115 
covariates at cART initiation: age, gender (M, F), nation of birth (native, migrant), 116 
(Heterosexual, intravenous drug addicts-IDU-, men sex with men –MSM-, Other/unknown), 117 
hepatitis status (HCV-Ab+, HCVAb-, HBsAg+, HBsAg-, unknown), AIDS (yes no), (0-200 118 
201-350, 351-500, 500+) and viral load (<20.000, 20.000-100.000, 100.000-250.000, 119 
250.000+) and year of starting cART (2008-09, 2010-11, 2012-13, 2014-15), nucleoside pair 120 
(TDF/FTC, ABC/3TC) and third drug started (DRV/r, ATV/r, RAL).  The reference group was 121 
also changed to allow a three-way comparison between RAL, DRV/r and ATV/r.  122 
We have used a cause-specific hazards for the survival analysis. This was done under the non-123 
testable assumption that censoring due to virological failure is non informative (unrelated to) 124 
for the risk of stopping a drug because of other reasons (e.g. toxicity or simplification). 125 
Incidence rate of each endpoint was calculated as number of events over person-years follow-126 
up (PYFU).  127 
Patients with CD4 count at pre-cART and at 24 months ( +/- 4 months) were selected and 128 
compared with subjects without this information. To define if the immunological recovery was 129 
different among the 3 regimens, univariable and multivariable linear regression was used. The 130 
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following time-fixed covariates at cART initiation were considered: age, gender, nation of 131 
birth, mode of HIV transmission, hepatitis status, AIDS, CD4 count and viral load and year of 132 
starting cART, nucleoside pair and third drug started. 133 
 134 
Results 135 
Characteristics of the Study Population 136 
A total of 2,249 patients fulfilling the criteria of inclusion were studied: 985 (43.8%) 137 
initiated a first ART regimen including ATV/r, 1,023 (45.5%) DRV/r and 241 (10.7%) RAL.  138 
The median age at baseline was 40 years (IQR: 32-48), 21% were females, 22% migrants, 40% 139 
men who acquired HIV through sex with other men (MSM); 224 (10%) were HCV coinfected 140 
and 92 (4.1%) HBV coinfected. Median CD4 at treatment initiation was 277 cells/mmc (IQR: 141 
120-415), the proportion of subjects with baseline CD4 <200 was 37%. Median HIV-RNA at 142 
baseline was 4.9 log10 copies/mL (IQR: 4.3-5.4), 44% had a pre-treatment HIV-RNA 143 
>100,000 copies/mL.  144 
Patients on ATV/r- were less frequently males, less frequently Italian, more frequently HCV 145 
coinfected and started cART in earlier calendar years than patients given either DRV/r or RAL. 146 
Patients on DRV/r had the lowest median CD4 counts and highest median HIV-RNA copy 147 
levels. Patients on RAL including regimens were more frequently affected by comorbidities 148 
(24/241; 10%) than those initiating ATV/r (42/985; 4.3%) or DRV/r (52/1023; 5.1%) (p=.002).  149 
 Patients’ characteristics according to the third drug are shown in Table 1. 150 
Participants have been followed-up for a median of 3.6 years from ART initiation 151 
(interquartile range-IQR: 2.3-5.2) (ATV/r: 4.3, IQR: 2.7-5.7;   DRV/r: 3.4, IQR: 2.3-4.9; RAL: 152 
2.3, IQR: 1.5-3.5).  153 
 154 
Incidence rates of various endpoints 155 
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Over 5,431 person-years of follow-up (PYFU), 1,433 patients reached the composite end-point 156 
of treatment failure, resulting in a incidence rate of 26.1 (95%CI 24.8-27.5). 157 
Overall, the 3 year-probability of treatment failure was of 51.7%  (95%CI: 48.5-55.1) 158 
for ATV/r, 49.9% (95%CI: 46.6-53.3) for DRV/r and 60.5%  (95% CI:  53.2-68.0) for RAL 159 
(p=0.158). The 3 year-probability of virological failure 50 was 17.1%  (95%CI: 14.4-20.2) for 160 
ATV/r, 18.0%  (95%CI:  15.3-21.2) for DRV/r and 5.1% (95%: 2.5-10.0) for RAL (p=0.04). 161 
Finally, the 3 year-probability of treatment discontinuation due to toxicity was 21.7% 162 
(95%CI: 18.9-24.9) for ATV/r, 13.7% (95%CI:  11.3-16.6) for DRV/r and  4.1% (95% CI: 2.0-163 
8.0) for RAL (p<0.001). 164 
The Kaplan Meier’s curves of the risk of experiencing the various end-points, stratified for 165 
regimen, are shown in Figure 1.  166 
 167 
A total of 627 patients  (63.6%) discontinued ATV/r, 605 (59.1%) discontinued DRV/r 168 
and 125 (51.9%) RAL.  Discontinuation due to toxicity was the main cause of interruption in 169 
patients on ATV/r   (209 out of 627, 33.3%), while simplification was the main cause of 170 
discontinuation both for patients on DRV/r (276 out of 605 discontinuations; 45.6%), and for  171 
patients on RAL (59 out of 125 discontinuations, 47.2%)  (Table 2).  172 
The main cause of discontinuation were H hyperbilirubinemia for ATV/r, gastrointestinal 173 
intolerance and lipid abnormalities for DRV/r. Only 10 patients on RAL discontinued for 174 
toxicity, mainly due to allergic reactions, gastrointestinal complaints and nephrotoxicity (Table 175 
2).  176 
Factors associated with the risk of outcomes 177 
After adjusting for age, gender, nation of birth, mode of HIV transmission, hepatitis B and C 178 
coinfection, AIDS, baseline CD4 counts and HIV-RNA, year of starting cART and NRTI 179 
started, patients given ATV/r showed a 26% statistically significant higher risk of  treatment 180 
failure (adjusted Hazard Ratio (AHR): 1.26, 95%CI 1.11-1.43 p=0.001) compared to those 181 
initiating DRV/r. There was no evidence for a difference in treatment failure among 182 
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participants starting RAL as compared to those starting DRV/r (AHR 1.02, 95%CI 0.83-1.26 - 183 
p=0.83); the risk of treatment failure was lower among patients on RAL as compared to those 184 
on ATV/r (AHR 0.81, 95%CI 0.66-0.99 - p=0.05).   185 
Because there was evidence that the proportional hazard assumption might have been violated 186 
for this outcome (p=0.06), a sensitivity analysis was performed by including in the model the 187 
interaction between the type of treatment and survival time (fitted in the natural logarithmic 188 
scale). Results of this analysis were similar, showing again a higher risk of treatment failure in 189 
patients starting ATV/r (AHR: 1.26, 95%CI 1.11-1.43 p<0.001) compared to those initiating 190 
DRV/r; in contrast, only a trend for lower risk of treatment failure among patients starting RAL 191 
as compared to those initiating ATV/r was observed (AHR 0.83, 95%CI 0.67-1.03 - p=0.085). 192 
After controlling for the same set of potential confounding variables, when compared to 193 
DRV/r, the probability of virological failure with threshold at 50 copies/ml was significantly 194 
lower for people initiating RAL (AHR 0.46, 95%CI 0.24-0.87- p=0.02). The probability of 195 
virological failure was also significantly lower for people initiating RAL as compared to those 196 
initiating ATV/r (AHR 0.52, 95%CI 0.27-0.99- p=0.05). No differences in virological failure 197 
were observed between the two PI/r regimens (ATV/r: AHR 0.85 – 95%CI: 0.66-1.09- vs 198 
DRV/r). 199 
Initiation of ATV/r was associated with a higher risk of discontinuation because of 200 
toxicity (AHR: 2.09, 95%CI: 1.63-2.67; p<0.001) when compared to DRV/r. Finally, patients 201 
who started a RAL-based regimen were less likely to stop due to toxicity as compared to 202 
DRV/r (AHR: 0.37, 95%CI: 0.19-0.72; p=0.003) as well as compared to ATV/r (AHR: 0.18, 203 
95%CI: 0.09-0.34; p<0.001) (Table 3).  204 
CD4 count response 205 
A total of 1790 (79.6%) patients had a follow up of at least 2 years, and of these 1747 (97.6%) 206 
had ≥1 available CD4 count  at 2 year from treatment initiation (808 ATV/r, 796 DRV/r, 143 207 
RAL). Participants reaching 2 years of follow-up and with 2 year-CD4 available were less 208 
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frequently migrants, HCV and HBV co-infected and more frequently MSM; further, they were 209 
less frequently on RAL than patients with a shorter follow up.  210 
Although the three groups started with different median CD4 cell count/cmm (ATV/r 305 211 
DRV/r 254 RAL 369, p<0.001), the mean CD4 recovery was not different among groups 212 
(+18.3 [95% -6.0; +42.6] for ATV/r and +10.7 [95%CI -30.7; 52.0] for RAL compared to 213 
DRV/r).    After adjustment for baseline characteristics, ATV/r showed higher mean CD4 214 
recovery at 2 years (+27.2 [95%CI +2.27; +52.1]) as compared to DRV/r; RAL showed a 215 
higher mean CD4 recovery at 2 years as compared to DRV/r, although marginally statistically 216 
different  (+37.6 [95%CI -3.5; 78.7]). 217 
 218 
 219 
Discussion 220 
Our analysis substantially confirms and extends to a longer duration of follow-up the 221 
results of the ACTG 5257 trial in a clinical setting of HIV-infected persons seen for routine 222 
care in Italy.  223 
In detail,  our estimates of the incidence of treatment failure according to the three 224 
regimens were similar but not identical to those seen in the trial and showed  a higher risk of 225 
failure for patients starting ATV/r as compared to those initiating the other two regimens. In 226 
fact, the absolute estimates of failure in our analysis were considerably higher than those 227 
observed in the trial. However, in the trial the definition of treatment failure included 228 
virological failure but only discontinuation of drugs due to toxicity/intolerance. We preferred to 229 
use a broader definition of treatment failure including the discontinuations of the third drugs for 230 
any reasons, given the observational setting of our study and the possible misclassifications of 231 
reasons for discontinuation, and this might in part explain the higher frequency of treatment 232 
failure in the Icona cohort as compared to that seen in the trial. .    233 
 234 
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Further, patients from the ICONA cohort were only partially comparable to US patients 235 
enrolled in the ACTG trial: in ICONA, there were more subjects who acquired HIV infection 236 
by intravenous drug use (8.6% vs 2%) and less subjects who were infected through men to men 237 
sexual intercourse (39.7% vs 54% ) than in the ACTG trial, reflecting the known differences in 238 
the HIV epidemics in Italy vs USA [4]. The different case mix and the real-life setting of the 239 
ICONA patients, potentially enriched with a population of less adherent patients, might have 240 
also  contributed to the higher failure rates seen. .  241 
The probability of discontinuation because of toxicity was higher in our cohort as 242 
compared to the ACTG trial, but the trends were similar, with patients who started ATV/r 243 
showing the highest risk, DRV/r intermediate risk and RAL the lowest risk. The causes leading 244 
to discontinuation because of toxicity of the three drugs are largely expected, with a driving 245 
cause represented by hyperbilirubinemia for ATV/r, gastrointestinal complaints for DRV/r and 246 
allergic reactions (even if few) for RAL. Also with this respect, our analysis replicates the 247 
results seen in the trial.  248 
Further, in our analysis RAL appeared to be superior in terms of tolerability also, 249 
although to a less extent, to DRV/r. These data are partly unexpected because patients on RAL 250 
showed a higher frequency of comorbidities at treatment initiation. The possible toxic effect of 251 
the drug is therefore difficult to disentangle from an apparent channelling bias  [7-9]. This was 252 
replicated in our multivariable analysis  which, after controlling for baseline imbalances 253 
between groups, showed identical results. 254 
When we looked at pure virological failure, patients receiving RAL-including 255 
combinations showed a 50% reduction in risk of failure as compared to those receiving DRV/r; 256 
there was no evidence for a difference in virological failure when comparing the two PI/r 257 
against each other. In contrast, the analysis of the trial shows no differences in the rate of 258 
virological failure between the three arms regardless of the threshold chosen to define viral 259 
failure (50 or 200 copies/mL). Because of the known limitation of adjusting for confounders by 260 
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multivariable analysis, we cannot rule out that the reduced risk of failure of RAL recipients in 261 
our analysis was partly due to this imbalance at baseline.   262 
To our knowledge there are no data verifying the reliability of the ACTG 5257  in  263 
clinical settings, even if all regimens have been widely used as first-line. Davis at al [1410] 264 
demonstrated that RAL-based regimens have a lower cost for successfully treated patients 265 
compared to DRV/r or ATV/r as first-line regimens in Spain. The STARTMRK [11] 266 
demonstrated the high virological potency and tolerability of RAL in naïve patients, with 81% 267 
of virologically controlled patients over 96 weeks-follow up. Other information can be derived 268 
by observational studies on individual regimens. A recent study from US [12] showed that the 269 
probability to be alive and virologically suppressed among patients on RAL was of 71% at 2 270 
years, data not different from what found in our cohort (showing 26% of incidence of treatment 271 
failure in a median follow up of 3 years). The Swiss cohort published recently a paper showing 272 
few discontinuations due to toxicity in both RAL and dolutegravir-receiving patients [ 13]. In 273 
particular, the main cause of discontinuation for RAL was convenience, similar to our findings 274 
showing simplification as main cause of discontinuation. In a previous analysis on late 275 
presenters from the ICONA cohort  we demonstrated a similar probability of treatment failure 276 
in participants on DRV/r and on ATV/r, both resulting in a better response as compared to 277 
lopinavir/r given patients [14]. Both DRV/r and ATV/r have been demonstrated to be highly 278 
effective in registration trials in comparison to LPV/r [15-16].  In the US setting, there were no 279 
differences in the durability of ATV/r and DRV/r regimens [17]. Patients’ and physicians’ 280 
concerns on hyperbilirubinemia together with the availability of other options might have 281 
affected the higher probability of treatment failure and discontinuation for toxicity in our data 282 
set as compared to previous ones.  283 
Unexpectedly, we found that ATV/r given patients had a better 2-year CD4 recovery as 284 
compared to other groups. In contrast, the trial shows a better immune recovery in the RAL 285 
arm; there are a number of possible explanations for this discrepancy, including possible 286 
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selection bias, the relatively small numbers in the RAL group, and, of course, unmeasured 287 
confounding.    288 
Our study has several limitations: first, because this is not a randomised study, 289 
channelling bias cannot be ruled out; indeed there was an imbalance between treatment arms 290 
even in measured potential confounders: for example; RAL was more likely given to 291 
participants with less advanced HIV diseases but with more comorbidities. Although we have 292 
accounted for these difference in the multivariable analysis, residual confounding might exist.   293 
  The major strengths of our analysis are the real life composition of the study 294 
population, the possibility to compare the treatment strategy in a setting with free-access to care 295 
and the long-term follow-up (on average one year longer than the trial). Indeed, we believe that 296 
the most important aspect of our analysis is that it was conducted in Italy so results should be 297 
less affected by bias due to socio-economic factors limiting patients’ adherence to expensive 298 
treatment like in the USA trial setting.  299 
In conclusion, our analysis shows higher absolute risks of failure for all regimens 300 
studied compared to those estimated in the randomised comparison but this discrepancy is 301 
largely attributable to the difference in the definition of the main endpoint used and the case-302 
mix of the study population. More importantly, the analysis confirms in the real-life setting, the 303 
lower tolerability and higher rate of discontinuation of ATV/r compared to DRV/r and RAL 304 
observed in the trial. In addition, we found a clear signal that RAL might be superior to both 305 
PI/r-based regimens with respect to tolerability and risk of virological failure with a threshold 306 
of >50 copies/mL.   307 
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Figure 1. Kaplan Meier curves estimating cumulative probability of various end-points 
according to drug regimens started. 
Figure Click here to download Figure Fig1_HCT_rev2  def.tif 
Table 1. Main characteristics of 2,249 patients according to the third drug started at their first antiretroviral 
regimen 
 
ATV/r DRV/r RAL p-value* Total 
 
N=985 N=1,023 N=241 
 
N=2,249 
Gender, n(%)      
Male 745 (75.6%) 835 (81.6%) 196 (81.3%) 0.003 1,776 (79.0%) 
Age, yrs, median (IQR) 39 (32-47) 40 (33-49) 43 (35-50) <0.001 40 (32-48) 
Migrants, n (%) 240 (24.4%) 209 (20.4%) 42 (17.4%) 0.022 491 (21.8%) 
Mode of HIV transmission, n(%)       
  Heterosexual 450 (45.7%) 426 (41.6%) 106 (44.0%) <0.001 982 (43.7%) 
IDU 118 (12.0%) 62 (6.1%) 14 (5.8%) 
 
194 (8.6%) 
MSM 354 (35.9%) 436 (42.6%) 102 (42.3%) 
 
892 (39.7%) 
Other/unknown 63 (6.4%) 99 (9.7%) 19 (7.9%) 
 
181 (8.0%) 
AIDS diagnosis, n(%) 88 (8.9%) 164 (16.0%) 29 (12.0%) <0.001 281 (12.5%) 
≥1 Comorbidity, n(%) 42 (4.3%) 52 (5.1%) 24 (10.0%) 0.002 118 (5.2%) 
Time from HIV diagnosis to first cART, 
months, median (IQR) 4 (1-32) 2 (1-17) 3 (1-24) <0.001 3 (1-24) 
HCV co-infection, n(%)       
  Positive 125 (12.7%) 80 (7.8%) 19 (7.9%) 0.001 224 (10.0%) 
Negative 769 (78.1%) 830 (81.1%) 188 (78.0%) 
 
1787 (79.5%) 
Not tested 91 (9.2%) 113 (11.1%) 34 (14.1%) 
 
238 (10.5%) 
HBV co-infection, n(%)       
  Positive 41 (4.2%) 37 (3.6%) 14 (5.8%) 0.311 92 (4.1%) 
Negative 818 (83.1%) 833 (81.4%) 190 (78.8%) 
 
1841 (81.9%) 
Not tested 126 (12.8%) 153 (15.0%) 37 (15.4%)  316 (14.0%) 
CD4 cell/cmm, n (%)            
 0-200 312 (31.7%) 443 (43.3%) 68 (28.2%) <0.001 823 (36.6%) 
201-350 299 (30.4%) 228 (22.3%) 49 (20.3%)   576 (25.6%) 
351-500 218 (22.1%) 207 (20.2%) 48 (19.9%)   473 (21.0%) 
>501 135 (13.7%) 120 (11.7%) 66 (27.4%)   321 (14.3%) 
Not available 21 (2.1%) 25 (2.4%) 10 (4.2%)   56 (2.5%) 
CD4 cell/cmm, mean (SD)  306 (205) 263 (210)  375 (273)  <0.001  294 (218)  
CD4 cell/cmm, median (IQR) 300 (152-410) 244 (80-394) 346 (153-532) <0.001 277 (120-415) 
HIV RNA copies/mL, n(%)         
 50-20,000 247 (25.1%) 210 (20.5%) 68 (28.2%) 0.001 525 (23.3%) 
20,000-100,000 308 (31.3%) 269 (26.3%) 78 (32.4%)   655 (29.1%) 
100,000-250,000 181 (18.4%) 209 (20.4%) 34 (14.1%)   424 (18.8%) 
>250,000 213 (21.6%) 301 (29.4%) 51 (21.2%)   565 (25.1%) 
Not available 36 (3.7%) 34 (3.3%) 10 (4.2%)   80 (3.6%) 
HIV RNA log
10 
copies/mL, median (IQR) 4.8 (4.3-5.3) 5.0 (4.5-5.5) 4.8 (4.2-5.3) <0.001 4.9 (4.3-5.4) 
Calendar year of cART start, n(%)         
 2008-2009 98 (9.9%) 12 (1.2%) 14 (5.8%) <0.001 124 (5.5%) 
2010-2011 354 (35.9%) 265 (28.7%) 28 (11.6%)     647 (28.8%) 
2012-2013 356 (36.1%) 403 (39.4%) 52 (21.6%)     811 (36.1%) 
2014-2015 177 (18.0%) 343 (33.5%) 147 (61.0%)     667 (29.7%) 
NRTI pair, n(%)         
 Tenofovir/Emtricitabine 852 (86.5%) 886 (86.6%) 207 (85.9%) 0.958 1945 (86.5%) 
Abacavir/Lamivudine 133 (13.5%) 137 (13.4%) 34 (14.1%)   304 3.5%) 
* Chi-square or Kruskal-Wallis test as appropriate 
NRTI=nucleoside reverse transcriptase inhibitors 
 
IDU=intravenous drug addicts 
MSM=men sex with men 
 
table 1 no tracks
Table 2. All causes of discontinuation and details of causes of discontinuation due to toxicity according to 
the regimen given 
 
All Causes of Discontinuation 
ATV/r DRV/r  RAL  Total  
N=627 N=605 N=125 N=1357 
Simplification 184 (29.4%) 276 (45.6%) 59 (47.2%) 519 (38.2%) 
Toxicity 209 (33.3%) 124 (20.5%) 10 (8.0%) 343 (25.3%) 
Other 70 (11.2%) 72 (11.9%) 11 (8.8%) 153 (11.3%) 
Missing 38 (6.1%) 39 (6.5%) 9 (7.2%) 86 (6.3%) 
Failure 50 (8.0%) 26 (4.3%) 7 (5.6%) 83 (6.1%) 
Patient’s decision 39 (6.2%) 23 (3.8%) 11 (8.8%) 73 (5.4%) 
Clinical trial 14 (2.2%) 26 (4.3%) 11 (8.8%) 51 (3.8%) 
Structured Treatment Interruption 18 (2.9%) 13 (2.2%) 6 (4.8%) 37 (2.7%) 
Pregnancy 4 (0.6%) 4 (0.7%) 1 (0.8%) 9 (0.7%) 
Death 1 (0.2%) 2 (0.3%) 0 (0.0%) 3 (0.2%) 
     
Causes of Discontinuation due 
to Toxicity 
ATV/r  DRV/r  RAL  Total  
N=209 N=124 N=10 N=343 
Gastrointestinal Toxicity 31 (14.8%) 35 (28.2%) 2 (20.0%) 68 (19.8%) 
Hyperbilirubinemia 58 (27.8%) 0 (0.0%) 0 (0.0%) 58 (16.9%) 
Allergic Reactions / Rash 26 (12.4%) 24 (19.3%) 2 (20.0%) 52 (15.2%) 
Lipid Metabolism Toxicity 15 (7.2%) 35 (28.2%) 0 (0.0%) 50 (14.6%) 
Others 20 (9.6%) 15 (12.1%) 3 (30.0%) 38 (11.1%) 
Hepatotoxicity *  28 (13.4%) 6 (4.8%) 0 (0.0%) 34 (9.9%) 
Nephroxicity 23 (11.0%) 6 (4.8%) 2 (20.0%) 31 (9.0%) 
Osteopenia / Osteoporosis 4 (1.9%) 3 (2.4%) 1 (10.0%) 8 (2.3%) 
Toxicity Not Specified 4 (1.9%) 0 (0.0%) 0 (0.0%) 4 (1.2%) 
 
*Hepatotoxicity other than hyperbilirubinemia 
 
  
 
Table 2
Table 3. Hazard ratio from fitting three separate Cox regression models.  
 
 
# event 
 
PYFU 
Crude 
 HR (95%CI) p-value  
Adjusted*  
HR (95%CI) p-value  
TF (HIV-RNA>200 copies/mL or discontinuation)         
DRV/r 
623 
(43 VF200, 580 D) 
 
2504 
1.00   1.00   
ATV/r 
679 
(65 VF200, 614 D) 
 
2497 
1.08 (0.96-1.22) 0.200 1.26 (1.11-1.43) 0.001 
RAL 
131 
(3 VF200, 128 D) 
 
430 
1.17 (0.96-1.42) 0.129 1.02 (0.83-1.26) 0.833 
VF50 (HIV-RNA>50 copies/mL)           
DRV/r 149 2325 1.00   1.00   
ATV/r 154 2426 0.85 (0.66-1.09) 0.212 0.88 (0.67-1.15) 0.345 
RAL 11 440 0.38 (0.20-0.71) 0.003 0.46 (0.24-0.87) 0.018 
Discontinuation due to toxicity  
 
        
DRV/r 124 2351 1.00   1.00   
ATV/r 209 2403 1.79 (1.42-2.27) <0.001 2.09 (1.63-2.67) <0.001 
RAL 10 422 0.42 (0.22-0.81) 0.010 0.37 (0.19-0.72) 0.003 
*Each model adjusted for age, gender, nation of birth, mode of HIV transmission, hepatitis co-infection status, AIDS 
diagnosis, nucleoside pair started,  baseline CD4 count and viral load and year of starting cART. 
 
(  TF= treatment failure, VF=virological failure, VF200=HIV-RNA>200 copies/mL, D=discontinuation, 
PYFU=person-years follow-up, HR=hazard ratio). 
 
 
 
 
table 3 no tracks
